We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MannKind has shifted the research and development (R&D) resources allotted for its lung diseases pipeline to help fight respiratory viral infections, including Covid-19.